An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Elderly (≥ 75 Years of Age) and Healthy Younger Adult Subjects (18 to 55 Years of Age, Inclusive)

Trial Profile

An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Elderly (≥ 75 Years of Age) and Healthy Younger Adult Subjects (18 to 55 Years of Age, Inclusive)

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Esketamine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 25 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 29 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top